Free Republic

IHU- Méditerranée Infection, Marseille, is a significant French research institute that has continued its work on CV 19. For the record, here are excerpts from some recent work, headlined from threads where such would be buried: EXH 1: >>COVID-IHU #15 Version 1 du 27 Mai 2020 Early diagnosis and management of COVID-19 patients: a real-life cohort study of 3,737 patients, Marseille, France Abstract Background: In our institute in Marseille, France, we proposed early and massive screening for coronavirus disease 2019 (COVID-19). Hospitalization and early treatment with hydroxychloroquine and azithromycin (HCQ-AZ) was proposed for the positive cases. Methods: We retrospectively report...

Results: The addition of zinc sulfate did not impact the length of hospitalization, duration of ventilation, or ICU duration. In univariate analyses, zinc sulfate increased the frequency of patients being discharged home, and decreased the need for ventilation, admission to the ICU, and mortality or transfer to hospice for patients who were never admitted to the ICU. After adjusting for the time at which zinc sulfate was added to our protocol, an increased frequency of being discharged home (OR 1.53, 95% CI 1.12-2.09) reduction in mortality or transfer to hospice remained significant (OR 0.449, 95% CI 0.271-0.744).

Oncologist and hematologist Dr. William Grace joins Laura Ingraham with reaction on 'The Ingraham Angle.' ( CLICK ABOVE LINK FOR THE VIDEO ). See the study here. TITLE: Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis Authored by Dr. Harvey Risch at the American Journal of Epidemiology. Abstract More than 1.6 million Americans have been infected with SARS-CoV-2 and >10 times that number carry antibodies to it. High-risk patients presenting with progressing symptomatic disease have only hospitalization treatment with its high mortality. An outpatient treatment that prevents hospitalization is...

The new study, of which the abstract was released today, was performed at IHU Méditerranée Infection, Marseille, France. A cohort of 1061 COVID-19 patients, treated for at least 3 days with the Hydroxychloroquine-Azithromycin (HCQ-AZ) combination and a follow-up of at least 9 days was investigated. Key findings are: No cardiac toxicity was observed.  A good clinical outcome and virological cure was obtained in 973 patients within 10 days (91.7%).  A poor outcome was observed for 46 patients (4.3%); 10 were transferred to intensive care units, 5 patients died (0.47%) (74-95 years old) and 31 required 10 days of hospitalization...

Currently, there is no known cure for the coronavirus pandemic ravaging the globe, but one possible remedy, the antimalarial drug hydroxychloroquine, has received increased attention in recent weeks. A new study aims to confirm whether or not that attention is warranted. The study, which will be conducted by the University of Washington in conjunction with New York University, looks to enroll 2,000 people who are "close contacts of persons with confirmed or pending COVID-19 diagnoses," according to a statement announcing the study. "We currently don’t know if hydroxychloroquine works, but we will learn in as short a timeframe as possible...

See latest statistics at link.

Last Wednesday, we published the success story from Dr. Vladimir Zelenko, a board-certified family practitioner in New York, after he successfully treated 350 coronavirus patients with 100 percent success using a cocktail of drugs: hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate. Now, Dr. Zelenko provides updates on the treatment after he successfully treated 699 COVID-19 patients in New York. In an exclusive interview with former New York Mayor, Rudy Giuliani, Dr. Vladmir Zelenko shares the results of his latest study, which showed that out of his 699 patients treated, zero patients died,...

The Hydroxy treatment appears to be working so far! In an exclusive interview, Dr. Vladmir Zelenko shares with us a preliminary study outlining that out of his 699 patients treated, he has had ZERO deaths, ZERO intubations, and four hospitalizations. In today's episode of Common Sense, Dr. Zelenko breaks it down and gives a lucid explanation of the rationale behind his treatment. If you have been following the COVID-19 outbreak, this is a do not miss! (VIDEO AT LINK DO NOT MISS!)

Abstract We need an effective treatment to cure COVID-19 patients and to decrease the virus carriage duration. In 80 in-patients receiving a combination of hydroxychloroquine and azithromycin we noted a clinical improvement in all but one 86 year-old patient who died, and one 74 year old patient still in intensive care unit. A rapid fall of nasopharyngeal viral load tested by qPCR was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient respiratory samples were negative in 97.5% patients at Day5. This allowed patients to rapidly de discharge from highly contagious wards with a mean...